3D PIB and CSF Biomarker Associations with Hippocampal Atrophy in ADNI Subjects

Overview

Journal Neurobiol Aging

Publisher Elsevier

Specialties Geriatrics
Neurology
Physiology

Date 2010 Jun 12

PMID 20538372

Citations 77

Authors

Liana G Apostolova

Kristy S Hwang

John P Andrawis

Amity E Green

Sona Babakchanian

Jonathan H Morra

Jeffrey L Cummings

Arthur W Toga

John Q Trojanowski

Leslie M Shaw

Clifford R Jack Jr

Ronald C Petersen

Paul S Aisen

William J Jagust

Robert A Koeppe

Chester A Mathis

Michael W Weiner

Paul M Thompson

Affiliations

Soon will be listed here.

Abstract

Cerebrospinal fluid (CSF) measures of Ab and tau, Pittsburgh Compound B (PIB) imaging and hippocampal atrophy are promising Alzheimer's disease biomarkers yet the associations between them are not known. We applied a validated, automated hippocampal labeling method and 3D radial distance mapping to the 1.5T structural magnetic resonance imaging (MRI) data of 388 ADNI subjects with baseline CSF Ab(42), total tau (t-tau) and phosphorylated tau (p-tau(181)) and 98 subjects with positron emission tomography (PET) imaging using PIB. We used linear regression to investigate associations between hippocampal atrophy and average cortical, parietal and precuneal PIB standardized uptake value ratio (SUVR) and CSF Ab(42), t-tau, p-tau(181), t-tau/Ab(42) and p-tau(181)/Ab(42). All CSF measures showed significant associations with hippocampal volume and radial distance in the pooled sample. Strongest correlations were seen for p-tau(181), followed by p-tau(181)/Ab(42) ratio, t-tau/Ab(42) ratio, t-tau and Ab(42). p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy.

Citing Articles

The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.

Nosheny R, Miller M, Conti C, Flenniken D, Ashford M, Diaz A Alzheimers Dement. 2024; 20(12):9004-9013.

PMID: 39535465 PMC: 11667550. DOI: 10.1002/alz.14311.

Neuroimaging correlates of Alzheimer's disease biomarker concentrations in a racially diverse high-risk cohort of middle-aged adults.

Misiura M, Munkombwe C, Igwe K, Verble D, Likos K, Minto L Alzheimers Dement. 2024; 20(9):5961-5972.

PMID: 39136298 PMC: 11497767. DOI: 10.1002/alz.14051.

The Relationship between SNAP25 and Some Common Human Neurological Syndromes.

Shu J, Peng F, Li J, Liu Y, Li X, Yuan C Curr Pharm Des. 2024; 30(30):2378-2386.

PMID: 38963116 DOI: 10.2174/0113816128305683240621060024.

MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.

Azam H, Rossling R, Geithe C, Khan M, Dinter F, Hanack K Front Mol Neurosci. 2024; 17:1386735.

PMID: 38883980 PMC: 11177777. DOI: 10.3389/fnmol.2024.1386735.

Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimer's disease.

Wu J, Shahid S, Lin Q, Hone-Blanchet A, Smith J, Risk B Front Aging Neurosci. 2022; 14:901140.

PMID: 36034141 PMC: 9413400. DOI: 10.3389/fnagi.2022.901140.

References

Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D . Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003; 60(12):1696-702. DOI: 10.1001/archneur.60.12.1696. View

Morris J, Roe C, Grant E, Head D, Storandt M, Goate A . Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009; 66(12):1469-75. PMC: 2798814. DOI: 10.1001/archneurol.2009.269. View

Hebert L, Beckett L, Scherr P, Evans D . Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord. 2001; 15(4):169-73. DOI: 10.1097/00002093-200110000-00002. View

Dickerson B, Sullivan M, Spanovic C, Wilson R, Bennett D . Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer's disease. Hippocampus. 2000; 10(2):136-42. DOI: 10.1002/(SICI)1098-1063(2000)10:2<136::AID-HIPO2>3.0.CO;2-J. View

Frisoni G, Prestia A, Zanetti O, Galluzzi S, Romano M, Cotelli M . Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimers Dement. 2009; 5(4):307-17. DOI: 10.1016/j.jalz.2009.04.1235. View

Jicha G, Parisi J, Dickson D, Johnson K, Cha R, Ivnik R . Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006; 63(5):674-81. DOI: 10.1001/archneur.63.5.674. View

Apostolova L, Dinov I, Dutton R, Hayashi K, Toga A, Cummings J . 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain. 2006; 129(Pt 11):2867-73. DOI: 10.1093/brain/awl274. View

Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E . Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol. 1995; 26(3):231-45. DOI: 10.1007/BF02815140. View

Frisoni G, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne J . In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology. 2009; 72(17):1504-11. DOI: 10.1212/WNL.0b013e3181a2e896. View

10.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B . Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001; 58(3):373-9. DOI: 10.1001/archneur.58.3.373. View

11.

Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y . Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009; 8(7):619-27. DOI: 10.1016/S1474-4422(09)70139-5. View

12.

de Leon M, DeSanti S, Zinkowski R, Mehta P, Pratico D, Segal S . Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2005; 27(3):394-401. DOI: 10.1016/j.neurobiolaging.2005.07.003. View

13.

Wegiel J, Tarnawski M, Bobinski M, Reisberg B, de Leon M, Miller D . Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol. 1997; 56(4):414-20. DOI: 10.1097/00005072-199704000-00010. View

14.

Buerger K, Teipel S, Zinkowski R, Blennow K, Arai H, Engel R . CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002; 59(4):627-9. DOI: 10.1212/wnl.59.4.627. View

15.

Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006; 5(3):228-34. DOI: 10.1016/S1474-4422(06)70355-6. View

16.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

17.

Jack Jr C, Petersen R, Xu Y, OBrien P, Smith G, Ivnik R . Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology. 1998; 51(4):993-9. PMC: 2768817. DOI: 10.1212/wnl.51.4.993. View

18.

Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

19.

Fleisher A, Grundman M, Jack Jr C, Petersen R, Taylor C, Kim H . Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005; 62(6):953-7. DOI: 10.1001/archneur.62.6.953. View

20.

Apostolova L, Dutton R, Dinov I, Hayashi K, Toga A, Cummings J . Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol. 2006; 63(5):693-9. DOI: 10.1001/archneur.63.5.693. View